{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/dyspepsia-proven-functional/prescribing-information/proton-pump-inhibitors/","result":{"pageContext":{"chapter":{"id":"c3d76d92-046e-5ac3-84fa-c59eff3cd774","slug":"proton-pump-inhibitors","fullItemName":"Proton pump inhibitors","depth":2,"htmlHeader":"<!-- begin field 53524d8d-0e5e-462d-bb5b-109a8644a9aa --><h2>Proton pump inhibitors</h2><!-- end field 53524d8d-0e5e-462d-bb5b-109a8644a9aa -->","summary":"","htmlStringContent":"<!-- begin item bbd55652-ed22-40f2-80ab-8383ec8b0df1 --><!-- end item bbd55652-ed22-40f2-80ab-8383ec8b0df1 -->","topic":{"id":"5cc1cb73-764f-51c5-bc62-44f807111272","topicId":"36754870-050c-4543-8dfe-bee25a1d10bb","topicName":"Dyspepsia - proven functional","slug":"dyspepsia-proven-functional","lastRevised":"Last revised in October 2018","chapters":[{"id":"8b6fdb09-e6f3-5061-8539-ae2f57647698","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"63a6aa45-5022-5194-bebc-bd4481b831fe","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"6cdc4376-525a-5e58-8be2-dd0831642d02","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"257ffcf8-d6ac-58d1-b852-f9bb7329f249","slug":"changes","fullItemName":"Changes"},{"id":"d05055eb-ebd0-5056-b860-1ea85daeb311","slug":"update","fullItemName":"Update"}]},{"id":"b6f4608e-164d-578d-8142-8b175799683f","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"bf8575af-2f9b-5729-a628-5efb1ed0411d","slug":"goals","fullItemName":"Goals"},{"id":"761ef9c0-39a0-5dd7-9216-2dc7963b0a6a","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"694c1d21-0d63-5dc6-bb90-b5acdbeb64ab","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"9244dd4a-0551-5975-b909-6d728dfadcdd","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"9029a91f-3843-5e59-8544-cb7adfa2c457","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"19b1713f-a518-57e7-a0c1-cdb48d0b4a0d","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"e265526e-adb9-5805-aedd-2e2bc77bb54c","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"93b80ba3-9d73-5fc5-8b0e-7a57de8d6107","slug":"definition","fullItemName":"Definition"},{"id":"8f596c75-9a83-5d33-8b9a-4d18a9e24e2e","slug":"prevalence","fullItemName":"Prevalence"},{"id":"0a9f461a-38b9-56d1-8511-e41e822e0e8a","slug":"complications","fullItemName":"Complications"},{"id":"e7524b44-b1cf-50d9-806d-bd52695ec307","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"a156deba-ce54-58e0-8984-13e20203cd70","fullItemName":"Management","slug":"management","subChapters":[{"id":"ff03390b-be65-558d-83cf-6808e0b84339","slug":"management-of-functional-dyspepsia","fullItemName":"Scenario: Management of functional dyspepsia"}]},{"id":"40a9d515-33a2-5915-b7db-28a3edf79724","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"c3d76d92-046e-5ac3-84fa-c59eff3cd774","slug":"proton-pump-inhibitors","fullItemName":"Proton pump inhibitors"},{"id":"8ad244d5-29e6-5577-8efb-eae73fd2faad","slug":"h2-receptor-antagonists","fullItemName":"H2-receptor antagonists"},{"id":"29d86046-683d-5047-a344-9b0961e8916a","slug":"amoxicillin","fullItemName":"Amoxicillin"},{"id":"891aafa8-13c0-5175-b0ac-580bd4cbe1b8","slug":"clarithromycin","fullItemName":"Clarithromycin"},{"id":"c11610d4-e4be-5dbb-baf5-5414f7bea599","slug":"metronidazole","fullItemName":"Metronidazole"},{"id":"a8c93904-08fc-57a4-b238-068ab96b5615","slug":"tetracycline","fullItemName":"Tetracycline"},{"id":"6075addb-8b4a-5e26-9d73-a9cd48dd70f3","slug":"levofloxacin","fullItemName":"Levofloxacin"},{"id":"348b1111-2664-52e1-9fd6-2d26abd69bcb","slug":"bismuth","fullItemName":"Bismuth"}]},{"id":"2d629b23-aa42-5503-980b-2c202de4c387","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"4be75458-608e-5c04-9441-7001ced7fc6d","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"6ad0185f-1607-5a33-9e94-892b09578c17","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"6489fce3-cac9-583f-a217-70ba5562de71","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"e29927f4-a004-5126-a503-f1045ce72a28","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"ca579371-2f3e-59ad-887e-7215f885a62a","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"de65b79c-b356-54be-a611-9a871e60c85e","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"43271e4f-f094-520d-bd20-f6582fc6ba97","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"40a9d515-33a2-5915-b7db-28a3edf79724","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"8e7b0e17-37b6-5251-a948-304efe219250","slug":"choice-of-proton-pump-inhibitor","fullItemName":"Choice of proton pump inhibitor","depth":3,"htmlHeader":"<!-- begin field 13323e37-edf6-43e8-85f3-051c6f3890f4 --><h3>Choice of proton pump inhibitor</h3><!-- end field 13323e37-edf6-43e8-85f3-051c6f3890f4 -->","summary":"","htmlStringContent":"<!-- begin item caacfb89-9b61-4583-a545-06fa147b89f2 --><!-- begin field 8eb455ae-563c-43fa-9e79-11b096032764 --><ul><li>Table 1 shows the recommended doses of proton pump inhibitors (PPIs) for the management of people with dyspepsia symptoms.</li></ul><p><strong>Table 1</strong><strong>. </strong>PPI doses for the management of people with dyspepsia symptoms.</p><table><thead><tr><th colspan=\"1\"><p>PPI</p></th><th colspan=\"1\"><p>Full or standard dose</p></th><th colspan=\"1\"><p>Low dose (on-demand dose)</p></th><th colspan=\"1\"><p>Double dose</p></th></tr></thead><tbody><tr><td colspan=\"1\">Omeprazole</td><td colspan=\"1\">20 mg once a day</td><td colspan=\"1\">* 10 mg once a day</td><td colspan=\"1\">40 mg once a day</td></tr><tr><td colspan=\"1\">Lansoprazole</td><td colspan=\"1\">30 mg once a day</td><td colspan=\"1\">15 mg once a day</td><td colspan=\"1\">* 30 mg twice a day</td></tr><tr><td colspan=\"1\">Pantoprazole</td><td colspan=\"1\">40 mg once a day</td><td colspan=\"1\">20 mg once a day</td><td colspan=\"1\">* 40 mg twice a day</td></tr><tr><td colspan=\"1\">Rabeprazole</td><td colspan=\"1\">20 mg once a day</td><td colspan=\"1\">10 mg once a day</td><td colspan=\"1\">* 20 mg twice a day</td></tr><tr><td colspan=\"1\">Esomeprazole</td><td colspan=\"1\">† 20 mg once a day</td><td colspan=\"1\">Not available</td><td colspan=\"1\">‡ 40 mg once a day</td></tr><tr><td colspan=\"4\">Doses should be given 30 minutes before breakfast and (if needed) 30 minutes before the evening meal, to provide optimal control of gastric pH.</td></tr><tr><td colspan=\"4\">* Off-label dose for GORD.</td></tr><tr><td colspan=\"4\">† This is lower than the licensed starting dose in GORD, but is considered to be dose-equivalent to other PPIs.</td></tr><tr><td colspan=\"4\">‡ This dose is recommended for double dose, because the 20 mg dose of esomeprazole is considered to be equivalent to omeprazole 20 mg.</td></tr><tr><td colspan=\"4\"><strong>Data from: [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-functional/references/\">NICE, 2014</a>]</strong></td></tr></tbody></table><!-- end field 8eb455ae-563c-43fa-9e79-11b096032764 --><!-- end item caacfb89-9b61-4583-a545-06fa147b89f2 -->","subChapters":[]},{"id":"a08fe2e0-3418-5871-ab8a-861f5dd66081","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 784a2f83-30b5-4419-af06-1a2b99401f1f --><h3>Contraindications and cautions</h3><!-- end field 784a2f83-30b5-4419-af06-1a2b99401f1f -->","summary":"","htmlStringContent":"<!-- begin item 57246266-4a87-4a1a-a7f5-cd03cf46e468 --><!-- begin field da8fb116-a2f6-479d-9dab-e25dcdceb4d9 --><ul><li><strong>Proton pump inhibitors (PPIs) should not be prescribed to people:</strong><ul><li>With alarm symptoms before endoscopy, as PPIs may mask the symptoms of upper gastrointestinal malignancy. If the person is already taking a PPI and subsequently needs an endoscopy, the PPI should be stopped at least 2 weeks before the procedure.</li></ul></li><li><strong>PPIs should be prescribed with caution to people:</strong><ul><li>At risk of osteoporosis — the person should maintain an adequate intake of calcium and vitamin D, and if necessary, be given additional bone-sparing therapy.</li><li>At risk of hypomagnesaemia — if possible, magnesium levels should be checked before starting PPI therapy and intermittently during long-term treatment, for example if the person is prescribed drugs that can cause hypomagnesaemia, such as digoxin and diuretics.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-functional/references/\">MHRA, 2012a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-functional/references/\">BNF 72, 2016</a>]</p><!-- end field da8fb116-a2f6-479d-9dab-e25dcdceb4d9 --><!-- end item 57246266-4a87-4a1a-a7f5-cd03cf46e468 -->","subChapters":[]},{"id":"651087f3-a7a5-5af1-ac98-567b30932ac6","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field eb3f6e50-68bf-4547-89b6-486876ae93fd --><h3>Adverse effects</h3><!-- end field eb3f6e50-68bf-4547-89b6-486876ae93fd -->","summary":"","htmlStringContent":"<!-- begin item 6bebfddf-5a80-469a-a6b5-51d7cd3dd640 --><!-- begin field 29792ede-366c-4158-b560-e9c61cd43d8b --><p><strong>Adverse effects of proton pump inhibitors (PPIs) are usually mild and reversible.</strong></p><ul><li>Adverse effects include headache, diarrhoea, nausea, vomiting, abdominal pain, constipation, and dizziness.</li><li>Less common adverse effects include dry mouth, peripheral oedema, sleep disturbance, fatigue, paraesthesia, arthralgia, myalgia, pruritus, and rash.</li><li>Rare or very rare adverse effects include:<ul><li>Subacute cutaneous lupus erythematosus (SCLE), which can occur weeks, months, or years after exposure to a PPI. If suspected discontinue the PPI and seek specialist advice if needed [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-functional/references/\">MHRA, 2015</a>].</li><li>Taste disturbance, hepatitis, jaundice, depression, confusion, hallucinations, hyponatraemia, leucopenia, leucocytosis, pancytopenia, thrombocytopenia, visual disturbances, sweating, photophobia, and alopecia.</li></ul></li><li>Long-term PPI treatment may be associated with uncommon, serious adverse effects such as:<ul><li>Hypomagnesaemia — symptoms include muscle twitching, tremors, vomiting, fatigue, and loss of appetite. Case reports after one year of PPI therapy, but may occur after 3 months. This usually improves after magnesium replacement therapy and discontinuation of the PPI [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-functional/references/\">MHRA, 2012a</a>].</li><li>Increased risk of fractures — especially when used at high doses for over a year in the elderly [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-functional/references/\">MHRA, 2012b</a>].</li><li><em>Clostridium difficile </em>infection — due to the effect of decreasing gastric acidity.</li><li>Rebound acid hypersecretion syndrome — may occur after stopping long-term PPI therapy, although this may be more a theoretical risk than clinical phenomenon.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-functional/references/\">NICE, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-functional/references/\">BNF 72, 2016</a>]</p><!-- end field 29792ede-366c-4158-b560-e9c61cd43d8b --><!-- end item 6bebfddf-5a80-469a-a6b5-51d7cd3dd640 -->","subChapters":[]},{"id":"a4487636-fb49-58bf-9b13-d792104bfe4b","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field c9d9b5df-c8dc-44d3-9176-246f9b447939 --><h3>Drug interactions</h3><!-- end field c9d9b5df-c8dc-44d3-9176-246f9b447939 -->","summary":"","htmlStringContent":"<!-- begin item d3fb864d-4579-427e-8f75-4824489e2dbe --><!-- begin field 08afbfc6-3940-4a46-987b-cb2b0dc79977 --><p><strong>Possible drug interactions with proton pump inhibitors (PPIs) include:</strong></p><ul><li><strong>Digoxin </strong>— PPIs may cause a small rise in serum digoxin levels (although not considered clinically significant). The manufacturer of lansoprazole suggests that digoxin levels should be monitored if lansoprazole is started or stopped.</li><li><strong>Warfarin </strong>— PPIs can occasionally enhance the effects of warfarin. The<strong> </strong>international normalized ratio (INR) should be monitored in people taking warfarin if omeprazole, pantoprazole, or esomeprazole is started or stopped.</li><li><strong>Methotrexate </strong>— PPIs possibly reduce excretion of methotrexate, leading to an increased risk of methotrexate toxicity.</li><li><strong>Phenytoin </strong>— omeprazole and esomeprazole can occasionally enhance the effects of phenytoin.<strong> </strong>The manufacturers recommend that people taking phenytoin are carefully monitored if omeprazole or esomeprazole is started or stopped.</li><li><strong>Azole antifungals </strong>— the absorption of ketoconazole or itraconazole may be reduced during PPI treatment. Dose adjustment of the antifungal drug may be required during long-term PPI treatment.</li><li><strong>Clopidogrel </strong>— omeprazole and esomeprazole reduce the antiplatelet effect of clopidogrel, and concomitant use should be avoided. The other PPIs may also reduce the efficacy of clopidogrel, and this risk should be weighed against the potential benefit of the PPI [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-functional/references/\">MHRA, 2010</a>].</li><li><strong>Protease inhibitors </strong>— PPIs can significantly affect plasma levels of some protease inhibitor drugs, including:<ul><li>Atazanavir — concurrent use of PPIs and atazanavir is not recommended as the absorption of atazanavir may be affected by a PPI (due to changes in gastric acidity). This may lead to a reduced plasma concentration of atazanavir which may affect its efficacy. If concurrent use is necessary, seek specialist advice.</li><li>Saquinavir — plasma concentration of saquinavir may be increased by PPI treatment, leading to increased risk of adverse effects.</li><li>Tipranavir — concurrent use with omeprazole or esomeprazole is not recommended, as tipranavir may reduce the plasma concentration of the PPI. If concurrent use is necessary, seek specialist advice.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-functional/references/\">Baxter, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-functional/references/\">BNF 72, 2016</a>]</p><!-- end field 08afbfc6-3940-4a46-987b-cb2b0dc79977 --><!-- end item d3fb864d-4579-427e-8f75-4824489e2dbe -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}